MCID: PRL017
MIFTS: 51

Prolymphocytic Leukemia

Categories: Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Prolymphocytic Leukemia

MalaCards integrated aliases for Prolymphocytic Leukemia:

Name: Prolymphocytic Leukemia 12 72 14 69
Leukemia, Prolymphocytic 41
Leukemia Prolymphocytic 51

Classifications:



External Ids:

Disease Ontology 12 DOID:1039
MeSH 41 D015463
NCIt 46 C3181
UMLS 69 C0023486

Summaries for Prolymphocytic Leukemia

MalaCards based summary : Prolymphocytic Leukemia, also known as leukemia, prolymphocytic, is related to t-cell prolymphocytic leukemia and b cell prolymphocytic leukemia. An important gene associated with Prolymphocytic Leukemia is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Epstein-Barr virus infection. The drugs Ketamine and Cefepime have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone, and related phenotypes are cellular and hematopoietic system

Wikipedia : 72 Prolymphocytic leukemia is divided into two types according to the kind of cell involved: B-cell... more...

Related Diseases for Prolymphocytic Leukemia

Diseases related to Prolymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 95)
# Related Disease Score Top Affiliating Genes
1 t-cell prolymphocytic leukemia 33.9 ATM MTCP1 MYC TCL1A
2 b cell prolymphocytic leukemia 31.7 CD19 CD38 CD5 FCER2 MYC ZAP70
3 lymphoma 30.2 ATM CCND1 MYC TCL1A
4 hairy cell leukemia 30.1 ADA CCND1 CD5
5 diffuse large b-cell lymphoma 29.8 CCND1 CD5 MYC
6 b-cell lymphomas 29.6 CCND1 CD5 MYC TCL1A
7 richter's syndrome 29.4 ATM CD38 CD5 MYC
8 anterior scleritis 29.4 CD19 CD5
9 b-cell expansion with nfkb and t-cell anergy 28.9 CD38 CD5 FCER2 ZAP70
10 mantle cell lymphoma 28.8 ATM CCND1 CD19 CD5 MYC
11 leukemia, chronic lymphocytic 27.2 ABCB4 ATM CCND1 CD19 CD38 CD5
12 splenic manifestation of prolymphocytic leukemia 12.1
13 leukemia 11.0
14 leukemia, chronic lymphocytic 2 10.4
15 leukemia, b-cell, chronic 10.4
16 primary effusion lymphoma 10.3 MYC TCL1A
17 adult lymphoma 10.3 CD5 MYC
18 lymphoid leukemia 10.2 CD5 ZAP70
19 synchronous bilateral breast carcinoma 10.2 ATM CCND1
20 hemimegalencephaly 10.2 CCND1 MYC
21 chromosome 13q14 deletion syndrome 10.2 CD38 ZAP70
22 lymphatic system cancer 10.1 CD5 MYC
23 cd45 deficiency 10.1 CD5 ZAP70
24 blood group, i system 10.1
25 t-cell leukemia 10.1
26 ataxia-telangiectasia 10.0
27 ataxia and polyneuropathy, adult-onset 10.0
28 hematopoietic stem cell transplantation 10.0
29 large granular lymphocyte leukemia 10.0
30 acquired immunodeficiency syndrome 10.0 ADA CD38 MYC
31 bladder lymphoma 9.9 CD19 CD5
32 colon lymphoma 9.9 CD19 CD5
33 kaposi sarcoma 9.9
34 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.9
35 graft-versus-host disease 9.9
36 autoimmune lymphoproliferative syndrome, type v 9.9
37 t-cell large granular lymphocyte leukemia 9.9
38 sarcoma 9.9
39 meningitis 9.9
40 t-cell lymphoma 1a 9.9
41 invasive malignant thymoma 9.9 CD19 CD38
42 solitary osseous plasmacytoma 9.8 CD19 CD38
43 gamma heavy chain disease 9.8 CD19 CD38
44 b-cell growth factor 9.8
45 hypercalcemia, infantile, 1 9.8
46 prostate cancer 9.8
47 anemia, autoimmune hemolytic 9.8
48 nijmegen breakage syndrome 9.8
49 mycobacterium tuberculosis 1 9.8
50 myocardial infarction 9.8

Graphical network of the top 20 diseases related to Prolymphocytic Leukemia:



Diseases related to Prolymphocytic Leukemia

Symptoms & Phenotypes for Prolymphocytic Leukemia

MGI Mouse Phenotypes related to Prolymphocytic Leukemia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.01 ABCB4 ADA ATM CCND1 CD19 CD38
2 hematopoietic system MP:0005397 9.96 ABCB4 ADA ATM CCND1 CD19 CD38
3 endocrine/exocrine gland MP:0005379 9.87 ABCB4 ADA ATM CCND1 CD38 MYC
4 digestive/alimentary MP:0005381 9.85 ABCB4 ADA CCND1 CD19 FCER2 MYC
5 immune system MP:0005387 9.85 CD5 FCER2 MYC ZAP70 ABCB4 ADA
6 integument MP:0010771 9.43 ATM CCND1 CD19 CD5 MYC ZAP70
7 neoplasm MP:0002006 9.02 CD19 MYC ABCB4 ATM CCND1

Drugs & Therapeutics for Prolymphocytic Leukemia

Drugs for Prolymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 270)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
3
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
4
Ofloxacin Approved Phase 3 82419-36-1 4583
5
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
6
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
7
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
8
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1 55-98-1 2478
9
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 38904 498142
10
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
11
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
12
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
13
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
14
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
15
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 209810-58-2, 11096-26-7
16
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
18
Dalteparin Approved Phase 3 9005-49-6
19
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
20
Ondansetron Approved Phase 3 99614-02-5 4595
21
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
22
Caspofungin Approved Phase 3,Phase 2 162808-62-0, 179463-17-3 2826718 468682
23
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
24
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
25
Morphine Approved, Investigational Phase 3 57-27-2 5288826
26
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
27 Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
28
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 460612 4053
29
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
30 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
31 Analgesics Phase 3,Phase 2
32 Anesthetics Phase 3
33 Anesthetics, Dissociative Phase 3
34 Anesthetics, General Phase 3
35 Anesthetics, Intravenous Phase 3
36 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
37 Excitatory Amino Acid Antagonists Phase 3
38 Excitatory Amino Acids Phase 3
39 Neurotransmitter Agents Phase 3
40 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
41 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
42 Anti-Infective Agents Phase 3,Phase 2,Phase 1
43 Cephalosporins Phase 3,Phase 1
44 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
45 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1,Phase 2
46 Renal Agents Phase 3,Phase 1,Phase 2
47 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
48 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
49 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
50 Antimetabolites Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 187)

# Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
3 Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia Completed NCT00003746 Phase 3 2-chlorodeoxyadenosine (CDA) daily;2-chlorodeoxyadenosine weekly
4 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
5 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
6 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
7 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
8 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
9 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
10 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
11 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
12 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
13 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
14 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
15 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
16 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
17 Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL) Completed NCT01186640 Phase 2 Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab;Alemtuzumab
18 Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Completed NCT00278213 Phase 2 cyclophosphamide;fludarabine phosphate;mitoxantrone hydrochloride
19 Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL) Completed NCT00464633 Phase 2 alvocidib
20 Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL Completed NCT00452374 Phase 1, Phase 2 Cytarabine;Fludarabine;Oxaliplatin;Rituximab
21 Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias Completed NCT00472849 Phase 1, Phase 2 Oxaliplatin;Fludarabine;Cytarabine;Rituximab;Pegfilgrastim
22 Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma Completed NCT00006252 Phase 2 fludarabine phosphate;Cyclophosphamide;G-CSF
23 Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL Completed NCT01217749 Phase 1, Phase 2 PCI-32765;ofatumumab
24 Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Completed NCT00060424 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
25 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
26 Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer Completed NCT00053196 Phase 2 busulfan;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus;allopurinol
27 Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825) Completed NCT00364286 Phase 2 Dasatinib (BMS-354825)
28 Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant Completed NCT01244906 Phase 2
29 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
30 Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer Completed NCT00782379 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
31 Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease Completed NCT00448201 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
32 Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen Completed NCT00448357 Phase 1, Phase 2 busulfan;fludarabine phosphate;tacrolimus;methotrexate
33 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
34 Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma Completed NCT00278161 Phase 2 cyclophosphamide
35 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
36 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
37 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
38 Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) Completed NCT00005626 Phase 2 Irinotecan
39 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
40 Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
41 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
42 Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Completed NCT00026351 Phase 2 pentostatin
43 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
44 Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults Completed NCT00001637 Phase 2
45 Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Recruiting NCT01251575 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
46 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting NCT02722668 Phase 2 Fludarabine;Cyclophosphamide;MMF;Sirolimus
47 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Recruiting NCT01008462 Phase 2 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
48 PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma Recruiting NCT02892695 Phase 1, Phase 2
49 Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma Recruiting NCT02851589 Phase 1, Phase 2
50 CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma Recruiting NCT02819583 Phase 1, Phase 2

Search NIH Clinical Center for Prolymphocytic Leukemia

Cochrane evidence based reviews: leukemia, prolymphocytic

Genetic Tests for Prolymphocytic Leukemia

Anatomical Context for Prolymphocytic Leukemia

MalaCards organs/tissues related to Prolymphocytic Leukemia:

38
T Cells, B Cells, Bone, Bone Marrow, Liver, Kidney, Myeloid

Publications for Prolymphocytic Leukemia

Articles related to Prolymphocytic Leukemia:

(show top 50) (show all 336)
# Title Authors Year
1
SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia. ( 29352181 )
2018
2
Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience. ( 29407180 )
2018
3
Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment. ( 28324286 )
2017
4
GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses. ( 28377595 )
2017
5
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). ( 28379307 )
2017
6
Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion. ( 28819574 )
2017
7
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. ( 28972014 )
2017
8
Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia. ( 28194886 )
2017
9
Risk of second cancers in survivors of prolymphocytic leukemia: a SEER data analysis. ( 27924652 )
2017
10
TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy. ( 28232160 )
2017
11
T-cell Prolymphocytic Leukemia. ( 28340878 )
2017
12
Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified. ( 28129454 )
2017
13
Development of B-cell prolymphocytic leukemia in a patient with splenic diffuse red pulp small B-cell lymphoma. ( 29199492 )
2017
14
Advances in the understanding and management of T-cell prolymphocytic leukemia. ( 29262669 )
2017
15
T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib). ( 29296924 )
2017
16
The distinctive cytological features of T-cell prolymphocytic leukemia. ( 28120343 )
2017
17
Linear nonpalpable purpura in a young male: a unique presentation of leukemia cutis in T-cell prolymphocytic leukemia. ( 28083939 )
2017
18
A 80-Year-Old Woman with B-Cell Prolymphocytic Leukemia. ( 28435655 )
2017
19
Broken heart by T-prolymphocytic leukemia. ( 28775161 )
2017
20
Modified Hyper-CVAD Regimen Followed by Autologous Peripheral Blood Stem Cell Transplantation Successfully Treated Synchronous T-Cell Prolymphocytic Leukemia and Gastric Cancer in a 68-Year-Old Female. ( 28824253 )
2017
21
Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations. ( 28695755 )
2017
22
T-cell prolymphocytic leukemia and tuberculosis: a puzzling association. ( 28878921 )
2017
23
Bullous leukemia cutis in a patient with T-cell prolymphocytic leukemia. ( 27504481 )
2016
24
Small Cell Variant of T-Cell Prolymphocytic Leukemia with Acquired Palmoplantar Keratoderma and Cutaneous Infiltration. ( 26813734 )
2016
25
Intraocular T-cell Prolymphocytic Leukemia Masquerading as Necrotizing Herpetic Retinitis. ( 27736276 )
2016
26
PEITC in End-Stage B-Cell Prolymphocytic Leukemia: Case Report of Possible Sensitization to Salvage R-CHOP. ( 27168399 )
2016
27
Brentuximab Vedotin Therapy for Cutaneous Lesions in T-Prolymphocytic Leukemia: A Case Report. ( 27757215 )
2016
28
GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses. ( 27941777 )
2016
29
T-cell chronic lymphocytic leukemia/T-prolymphocytic leukemia: Experience with single agent bendamustine. ( 26853400 )
2015
30
Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia. ( 26109102 )
2015
31
Encephalitozoon hellem in a patient with CD4(+) T-cell prolymphocytic leukemia: case report and genomic identification. ( 26299583 )
2015
32
T-cell prolymphocytic leukemia presenting with leukemic serous effusion in a prostate cancer patient. ( 26881553 )
2015
33
Auer Rod-Like Inclusions in Prolymphocytic Leukemia. ( 26299084 )
2015
34
Interleukin-2-inducible T-cell Kinase (ITK) Targeting by BMS-509744 Does Not Affect Cell Viability in T-cell Prolymphocytic Leukemia (T-PLL). ( 25888568 )
2015
35
A T-cell prolymphocytic leukemia case with central nervous system involvement. ( 26550397 )
2015
36
Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: AA Single-Center Experience. ( 26422251 )
2015
37
Expression of S100 Protein in CD4-positive T-cell Lymphomas Is Often Associated With T-cell Prolymphocytic Leukemia. ( 26379148 )
2015
38
A I^/I' T-cell Receptor Prolymphocytic Leukemia and CD4-/CD8- Double-negative Immunophenotype in a Pediatric Patient. ( 25757027 )
2015
39
T-cell prolymphocytic leukemia: survival improves with alemtuzemab, but stem cell transplant eligibility 'counts' even more. ( 26293613 )
2015
40
T-Cell Prolymphocytic Leukemia, Small Cell Variant, Possibly at the Stage of Intracytoplasmic Expression of CD3 in T-Cell Ontogenesis. ( 26106002 )
2015
41
A pediatric case of T-cell prolymphocytic leukemia. ( 25417638 )
2015
42
Survival trends in T cell prolymphocytic leukemia: A SEER database analysis. ( 26292711 )
2015
43
Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation? ( 25712069 )
2015
44
Management of prolymphocytic leukemia. ( 26637744 )
2015
45
T-cell chronic lymphocytic leukemia or small-cell variant of T-cell prolymphocytic leukemia: a historical perspective and search for consensus. ( 25846234 )
2015
46
Successful allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for B-cell prolymphocytic leukemia in partial remission. ( 24470149 )
2014
47
Functional analysis of the SEPT9-ABL1 chimeric fusion gene derived from T-prolymphocytic leukemia. ( 25217890 )
2014
48
B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma. ( 24891323 )
2014
49
T-cell Prolymphocytic Leukemia Frequently Shows Cutaneous Involvement and Is Associated With Gains of MYC, Loss of ATM, and TCL1A Rearrangement. ( 25310835 )
2014
50
Infiltration of the thyroid gland by T-cell prolymphocytic leukemia. ( 24762052 )
2014

Variations for Prolymphocytic Leukemia

Expression for Prolymphocytic Leukemia

Search GEO for disease gene expression data for Prolymphocytic Leukemia.

Pathways for Prolymphocytic Leukemia

GO Terms for Prolymphocytic Leukemia

Cellular components related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 ADA CD19 CD5 FCER2

Biological processes related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.8 ADA CD38 MYC TCL1A
2 liver regeneration GO:0097421 9.52 CCND1 MYC
3 response to morphine GO:0043278 9.51 ABCB4 ADA
4 positive regulation of T cell differentiation GO:0045582 9.48 ADA ZAP70
5 positive regulation of calcium-mediated signaling GO:0050850 9.46 ADA ZAP70
6 response to hypoxia GO:0001666 9.46 ABCB4 ADA ATM CD38
7 positive regulation of response to DNA damage stimulus GO:2001022 9.43 ATM MYC
8 response to vitamin E GO:0033197 9.4 ADA CCND1
9 positive regulation of alpha-beta T cell differentiation GO:0046638 9.37 ADA ZAP70
10 response to drug GO:0042493 9.35 ABCB4 ADA CCND1 CD38 MYC
11 positive regulation of mitochondrial membrane potential GO:0010918 9.32 MYC TCL1A
12 re-entry into mitotic cell cycle GO:0000320 9.26 CCND1 MYC
13 response to estradiol GO:0032355 8.92 ABCB4 CCND1 CD38 MYC

Molecular functions related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein serine/threonine kinase activator activity GO:0043539 8.62 MTCP1 TCL1A

Sources for Prolymphocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....